Groupama Asset Managment Buys 156,979 Shares of Boston Scientific Corporation $BSX

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Groupama Asset Managment lifted its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 13.7% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,300,910 shares of the medical equipment provider's stock after purchasing an additional 156,979 shares during the quarter. Boston Scientific accounts for about 1.0% of Groupama Asset Managment's investment portfolio, making the stock its 22nd largest holding. Groupama Asset Managment owned 0.09% of Boston Scientific worth $129,258,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. NS Partners Ltd boosted its position in shares of Boston Scientific by 1.6% in the 1st quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider's stock valued at $37,143,000 after purchasing an additional 5,704 shares during the period. Bank Pictet & Cie Europe AG boosted its position in shares of Boston Scientific by 40.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after purchasing an additional 21,173 shares during the period. Oppenheimer & Co. Inc. boosted its position in shares of Boston Scientific by 18.8% in the 1st quarter. Oppenheimer & Co. Inc. now owns 39,523 shares of the medical equipment provider's stock valued at $3,987,000 after purchasing an additional 6,264 shares during the period. Segall Bryant & Hamill LLC acquired a new position in shares of Boston Scientific in the 1st quarter valued at $8,234,000. Finally, Blue Trust Inc. boosted its position in shares of Boston Scientific by 13.0% in the 1st quarter. Blue Trust Inc. now owns 5,000 shares of the medical equipment provider's stock valued at $504,000 after purchasing an additional 575 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Stock Up 0.7%

Shares of Boston Scientific stock traded up $0.7850 during trading on Friday, hitting $105.9950. 9,396,775 shares of the stock traded hands, compared to its average volume of 6,321,979. The stock has a market cap of $157.06 billion, a P/E ratio of 63.09, a PEG ratio of 2.56 and a beta of 0.66. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a twelve month low of $78.53 and a twelve month high of $108.94. The company has a fifty day moving average price of $104.10 and a two-hundred day moving average price of $102.12.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm's revenue was up 22.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the transaction, the executive vice president directly owned 178,342 shares of the company's stock, valued at approximately $18,659,923.46. This trade represents a 21.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael F. Mahoney sold 164,443 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $103.69, for a total value of $17,051,094.67. Following the completion of the transaction, the chief executive officer directly owned 1,476,882 shares in the company, valued at $153,137,894.58. The trade was a 10.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 345,029 shares of company stock worth $35,976,603 over the last quarter. Insiders own 0.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on BSX shares. Citigroup reiterated a "buy" rating and issued a $125.00 price target (up previously from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Erste Group Bank upgraded Boston Scientific to a "strong-buy" rating in a research report on Thursday, May 8th. Leerink Partners assumed coverage on Boston Scientific in a research report on Monday, June 16th. They set an "outperform" rating and a $118.00 price objective for the company. Leerink Partnrs upgraded Boston Scientific to a "strong-buy" rating in a research report on Monday, June 16th. Finally, Raymond James Financial raised their price objective on Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research report on Thursday, July 24th. Three analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $117.50.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.